NEW ADENOVIRUS SYSTEM FOR EASY BLUE/WHITE SCREENING OF RECOMBINANTS

Qbiogene announces the release of its latest kit for the production of recombinant adenovirus: the Transpose-Ad™ Adenoviral Vector System, licensed from GlaxoSmithKline, North Carolina. The Transpose-Ad™ system utilizes the site-specific transposon Tn7 to generate pure clonal stocks of recombinant adenovirus. The Transpose-Ad™ plasmid contains the E1/E3 adenovirus serotype 5 genome, in which the Tn7 specific attachment site, attTn7, is strategically positioned in the lacZ gene. Therefore, the screening of recombinants in bacterial cells is based on the familiar white/blue selection, making this system even more convenient. The major advantage of this new approach is that plaque purification is not required, since the virus obtained after transfection is a pure, clonal stock of recombinant adenovirus. This allows the researcher to save 3 weeks to a month work in preparation of a recombinant adenovirus. Like other Qbiogene adenovirus kits, the system uses the convenient E. coli cells as host. Hence, using both the bacterial transposon Tn7 and attTn7, the unique attachment site for Tn7 in E. coli, improves greatly the efficiency of the Transpose-Ad™ Adenoviral Vector System. The kit comes with two different transfer vectors one of which contains the human CMV IE (immediate early) promoter/enhancer, whereas the other transfer vector facilitates expression from a user-supplied promoter. Both vectors contain a multiple cloning site (MCS) as well as the SV40 poly A signal.

More on the Transpose-Ad System...